CR20190278A - Nuevos receptores de células t y terapia inmunológica que los utiliza - Google Patents
Nuevos receptores de células t y terapia inmunológica que los utilizaInfo
- Publication number
- CR20190278A CR20190278A CR20190278A CR20190278A CR20190278A CR 20190278 A CR20190278 A CR 20190278A CR 20190278 A CR20190278 A CR 20190278A CR 20190278 A CR20190278 A CR 20190278A CR 20190278 A CR20190278 A CR 20190278A
- Authority
- CR
- Costa Rica
- Prior art keywords
- antigen
- taa
- nucleic acids
- constructs
- tcr
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 7
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 6
- 238000009169 immunotherapy Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 9
- 108091007433 antigens Proteins 0.000 abstract 9
- 102000036639 antigens Human genes 0.000 abstract 9
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 abstract 2
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000009258 tissue cross reactivity Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464488—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
Abstract
La presente invención se relaciona con construcciones de reconocimiento de antígeno contra antígenos asociados a tumor (MAGEA1). La invención en particular provee nuevas moléculas basadas en el receptor de células T (TCR) que son selectivas y específicas para el antígeno expresado en tumores de la invención. Los TCR de la invención, y fragmentos de unión a TAA derivados de los mismos, se usan en el diagnóstico, tratamiento y prevención de enfermedades cancerosas que expresan TAA. Además se proveen ácidos nucleicos que codifican para las construcciones de reconocimiento de antígeno de la invención, vectores que comprenden estos ácidos nucleicos, células recombinantes que expresan las construcciones de reconocimiento de antígeno y composiciones farmacéuticas que comprenden los compuestos de la invenciónThe present invention pertains to antigen recognizing constructs against tumor associated antigens (MAGEA1). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662431588P | 2016-12-08 | 2016-12-08 | |
DE102016123847.3A DE102016123847B3 (de) | 2016-12-08 | 2016-12-08 | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
PCT/EP2017/081800 WO2018104438A1 (en) | 2016-12-08 | 2017-12-07 | Novel t cell receptors and immune therapy using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20190278A true CR20190278A (es) | 2019-11-19 |
Family
ID=61623755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20190278A CR20190278A (es) | 2016-12-08 | 2017-12-07 | Nuevos receptores de células t y terapia inmunológica que los utiliza |
Country Status (14)
Country | Link |
---|---|
US (1) | US10874731B2 (es) |
EP (1) | EP3551221B1 (es) |
KR (1) | KR20190088539A (es) |
CN (1) | CN110114085A (es) |
AU (2) | AU2017373740C1 (es) |
BR (1) | BR112019010972A2 (es) |
CA (1) | CA3045233C (es) |
CR (1) | CR20190278A (es) |
DE (1) | DE102016123847B3 (es) |
MA (1) | MA49236B1 (es) |
MX (1) | MX2019006724A (es) |
PE (1) | PE20191648A1 (es) |
TW (1) | TWI736719B (es) |
WO (1) | WO2018104438A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102375218B1 (ko) * | 2016-12-08 | 2022-03-17 | 이매틱스 바이오테크놀로지스 게엠베하 | T 세포 수용체 및 이를 사용하는 면역 요법 |
DE102016123847B3 (de) | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
EP3595708A4 (en) * | 2017-03-15 | 2020-12-16 | Fred Hutchinson Cancer Research Center | HIGHLY POTENTIAL MAGE-A1 SPECIFIC TCRS AND USES |
EP3670530A1 (en) * | 2018-12-18 | 2020-06-24 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies |
DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
EA202192726A1 (ru) | 2019-04-04 | 2022-01-26 | Медиджин Иммьюнотерапиз Гмбх | Magea1-специфические т-клеточные рецепторы и их использование |
CR20210669A (es) | 2019-05-27 | 2022-05-05 | Immatics Us Inc | Vectores víricos y uso de los mismos en terapias celulares adoptivas |
US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
GB201915282D0 (en) | 2019-10-22 | 2019-12-04 | Immunocore Ltd | Specific binding molecules |
JP2022554349A (ja) * | 2019-11-05 | 2022-12-28 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Hla拘束性hormad1 t細胞受容体およびその使用 |
CN111208304B (zh) * | 2020-01-20 | 2023-06-16 | 中国医学科学院北京协和医院 | 肿瘤来源IgG在甲状旁腺癌诊断和预后中的用途 |
AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
TW202227616A (zh) * | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | 分離cd8+選擇t細胞的方法 |
TW202241938A (zh) | 2020-12-31 | 2022-11-01 | 美商英麥提克斯股份有限公司 | Cd8多肽、組合物及其使用方法 |
WO2022233957A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
WO2023081925A1 (en) | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
WO2023081461A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
US20230310607A1 (en) | 2021-11-09 | 2023-10-05 | T-Knife Gmbh | Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits |
WO2023133296A2 (en) * | 2022-01-07 | 2023-07-13 | Sorrento Therapeutics, Inc. | Engineered pd-l1-targeting gamma delta t cell receptors |
WO2023175069A1 (en) * | 2022-03-16 | 2023-09-21 | Medigene Immunotherapies Gmbh | Tcr constant region pairing library for pramevld tcrs |
WO2023175070A1 (en) * | 2022-03-16 | 2023-09-21 | Medigene Immunotherapies Gmbh | Tcr constant region pairing library |
WO2023179795A1 (zh) * | 2022-03-25 | 2023-09-28 | 立凌生物制药(苏州)有限公司 | 一种快速且简便地获得正确配对tcr的方法以及获得的tcr |
WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
WO2023212697A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
CN116970066B (zh) * | 2023-09-19 | 2024-03-12 | 恒瑞源正(广州)生物科技有限公司 | Mage-a1特异性t细胞受体及其用途 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
EP1257289A1 (en) | 2000-02-08 | 2002-11-20 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
US20140378389A1 (en) * | 2011-09-15 | 2014-12-25 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
PT2951202T (pt) * | 2013-01-29 | 2020-07-07 | Max Delbruck Centrum Fur Molekulare Medizin Mdc Berlin Buch | Moléculas de ligação de alta avidez que reconhecem mage-a1 |
MX2015016963A (es) * | 2013-06-10 | 2016-08-08 | Dana Farber Cancer Inst Inc | Metodos y composiciones para reducir la inmunosupresion por celulas de tumor. |
US10202640B2 (en) * | 2014-05-07 | 2019-02-12 | The Board Of Trustees Of The Leland Stanford Junior University | Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing |
KR20170032406A (ko) | 2014-07-15 | 2017-03-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료를 위한 조작된 세포 |
CN105316362B (zh) * | 2015-08-19 | 2020-03-17 | 暨南大学 | 一种Dual-RMCE介导的TCR基因置换系统及其方法 |
GB201604492D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
CN106749620B (zh) | 2016-03-29 | 2020-09-25 | 广东香雪精准医疗技术有限公司 | 识别mage-a1抗原短肽的t细胞受体 |
JP6989138B2 (ja) | 2016-06-17 | 2022-01-05 | メディジーン イミュノテラピーズ ゲーエムベーハー | T細胞受容体及びその使用 |
DE102016123847B3 (de) | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
KR102375218B1 (ko) * | 2016-12-08 | 2022-03-17 | 이매틱스 바이오테크놀로지스 게엠베하 | T 세포 수용체 및 이를 사용하는 면역 요법 |
EP3595708A4 (en) | 2017-03-15 | 2020-12-16 | Fred Hutchinson Cancer Research Center | HIGHLY POTENTIAL MAGE-A1 SPECIFIC TCRS AND USES |
KR20200065026A (ko) | 2017-09-29 | 2020-06-08 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | P53 암-특이적 돌연변이에 대한 항원 특이성을 갖는 t 세포를 단리하는 방법 |
-
2016
- 2016-12-08 DE DE102016123847.3A patent/DE102016123847B3/de active Active
-
2017
- 2017-12-07 PE PE2019001076A patent/PE20191648A1/es unknown
- 2017-12-07 EP EP17829609.1A patent/EP3551221B1/en active Active
- 2017-12-07 AU AU2017373740A patent/AU2017373740C1/en active Active
- 2017-12-07 BR BR112019010972A patent/BR112019010972A2/pt unknown
- 2017-12-07 MX MX2019006724A patent/MX2019006724A/es unknown
- 2017-12-07 CR CR20190278A patent/CR20190278A/es unknown
- 2017-12-07 CA CA3045233A patent/CA3045233C/en active Active
- 2017-12-07 MA MA49236A patent/MA49236B1/fr unknown
- 2017-12-07 CN CN201780075284.2A patent/CN110114085A/zh active Pending
- 2017-12-07 US US15/834,633 patent/US10874731B2/en active Active
- 2017-12-07 WO PCT/EP2017/081800 patent/WO2018104438A1/en unknown
- 2017-12-07 KR KR1020197019005A patent/KR20190088539A/ko not_active IP Right Cessation
- 2017-12-08 TW TW106143114A patent/TWI736719B/zh active
-
2021
- 2021-05-14 AU AU2021203099A patent/AU2021203099A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20180161396A1 (en) | 2018-06-14 |
DE102016123847B3 (de) | 2018-04-05 |
PE20191648A1 (es) | 2019-11-07 |
WO2018104438A1 (en) | 2018-06-14 |
KR20190088539A (ko) | 2019-07-26 |
CN110114085A (zh) | 2019-08-09 |
EP3551221B1 (en) | 2021-11-10 |
EP3551221A1 (en) | 2019-10-16 |
AU2017373740B2 (en) | 2021-03-18 |
MA49236A (fr) | 2020-04-15 |
BR112019010972A2 (pt) | 2019-10-15 |
MX2019006724A (es) | 2019-08-22 |
AU2017373740C1 (en) | 2021-08-26 |
TWI736719B (zh) | 2021-08-21 |
TW201827458A (zh) | 2018-08-01 |
CA3045233C (en) | 2023-11-28 |
MA49236B1 (fr) | 2022-02-28 |
AU2021203099A1 (en) | 2021-06-10 |
US10874731B2 (en) | 2020-12-29 |
AU2017373740A1 (en) | 2019-06-27 |
CA3045233A1 (en) | 2018-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20190278A (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
CO2019006914A2 (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
CR20190276A (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
MX2023003463A (es) | Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame. | |
WO2018172533A3 (en) | T cell receptors and immune therapy using the same against prame positive cancers | |
MX2019001769A (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
PH12020550600A1 (en) | Novel engineered t cell receptors and immune therapy using the same | |
PH12019500312A1 (en) | T cell receptors and immune therapy using the same | |
MX2019015742A (es) | Receptores de celulas t novedosos, e inmunoterapia usando los mismos. | |
EA201992131A1 (ru) | Высокоаффинные специфичные к mage-a1 tcr и их применение | |
AR115389A1 (es) | Anticuerpo antagonista de cd73 | |
BR112017007093A2 (pt) | composições e métodos de uso para aumento da resposta imune e terapia do câncer | |
PH12019500571A1 (en) | Anti-pd-1 antibodies | |
MX2020001287A (es) | Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos. | |
CO2019006926A2 (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
EA202090712A1 (ru) | Новые полученные методами генной инженерии t-клеточные рецепторы и иммунная терапия с их использованием | |
NZ750479A (en) | T cell receptors and immune therapy using the same | |
AR110682A1 (es) | Receptores de células t y terapia inmunológica que los utiliza | |
EA201992002A1 (ru) | Т-клеточные рецепторы и иммунная терапия prame-положительных раковых заболеваний с их применением | |
AR113834A1 (es) | Receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos | |
AR110504A1 (es) | Receptores de células t y terapia inmunológica que los utiliza | |
UY36344A (es) | Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia del cáncer |